Print

Featured Studies Results

Comparing the Targeted Therapy Daraxonrasib With or Without Chemotherapy to Chemotherapy Alone for First-Line Treatment of Metastatic Pancreatic Cancer (RASolute 303)

https://www.facingourrisk.org/research-clinical-trials/study/407 /comparing-daraxonrasib-with-or-without-chemotherapy-to-chemotherapy-alone-for-first-line-treatment-of-metastatic-pancreatic-cancer

Clinicaltrials.gov identifier:
NCT07491445 (https://clinicaltrials.gov/show/NCT07491445)

Treatment
Phase 3 Study for First-Line Treatment of Metastatic Pancreatic Cancer

A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer who Progressed After a Prior Line of Treatment

https://www.facingourrisk.org/research-clinical-trials/study/414 /a-study-to-learn-about-the-study-medicine-called-pf-07248144-in-combination-with-fulvestrant-in-people-with-hr-positive-her2-negative-advanced-or-metastatic-breast-cancer-who-progressed-after-a-prior-line-of-treatment

Clinicaltrials.gov identifier:
NCT07062965 (https://clinicaltrials.gov/show/NCT07062965)

Treatment
Phase 3 study for adults with advanced/metastatic HR-positive, HER2-negative breast cancer who have progressed from prior treatment

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone or Darolutamide (TALENT)

https://www.facingourrisk.org/research-clinical-trials/study/425 /a-study-of-talazoparib-with-or-without-enzalutamide-in-people-with-prostate-cancer-who-have-previously-received-abiraterone-or-darolutamide-talent

Clinicaltrials.gov identifier:
NCT06844383 (https://clinicaltrials.gov/show/NCT06844383)

Treatment
Phase 2 study for metastatic castration-resistant prostate cancer with an HRR mutation

Testing COM701 Maintenance Treatment to Delay Cancer Growth After Platinum Chemotherapy for Ovarian Cancer That Has Come Back

https://www.facingourrisk.org/research-clinical-trials/study/381 /testing-com701-maintenance-treatment-to-delay-cancer-growth-after-platinum-chemotherapy-for-ovarian-cancer-that-has-come-back

Clinicaltrials.gov identifier:
NCT06888921 (https://clinicaltrials.gov/show/NCT06888921)

Treatment
Study for relapsed platinum-sensitive ovarian cancer

FIT Testing for Colorectal Cancer Screening in People with Lynch Syndrome

https://www.facingourrisk.org/research-clinical-trials/study/418 /fit-testing-for-colorectal-cancer-screening-in-people-with-lynch-syndrome

Clinicaltrials.gov identifier:
NCT06898996 (https://clinicaltrials.gov/show/NCT06898996)

Prevention
Colon cancer screening study for people with Lynch syndrome

Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies

https://www.facingourrisk.org/research-clinical-trials/study/356 /treating-advanced-msi-high-or-dmmr-cancers-using-the-targeted-therapy-moma-341-given-alone-or-in-combination-with-standard-therapies

Clinicaltrials.gov identifier:
NCT06974110 (https://clinicaltrials.gov/show/NCT06974110)

Treatment
Treatment study for people with advanced or metastatic cancers

A New Drug, DT2216, Combined With Paclitaxel for Recurrent Platinum-Resistant Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/429 /a-new-drug-dt2216-combined-with-paclitaxel-for-recurrent-platinum-resistant-ovarian-cancer

Clinicaltrials.gov identifier:
NCT06964009 (https://clinicaltrials.gov/show/NCT06964009)

Treatment
Phase 1b study for people with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

Testing an Acupressure App for Cancer Survivors with Fatigue and Sleep Problems

https://www.facingourrisk.org/research-clinical-trials/study/426 /decentralized-clinical-trial-of-effectiveness-of-energypoints-app-in-cancer-survivors

Clinicaltrials.gov identifier:
NCT06754722 (https://clinicaltrials.gov/show/NCT06754722)

Quality of Life
Remote clinical trial enrolling adult cancer survivors with cancer-related fatigue and sleep disturbances

Research Study on the Genetics of Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/317 /research-study-on-the-genetics-of-breast-cancer

Clinicaltrials.gov identifier:
NCT06773897 (https://clinicaltrials.gov/show/NCT06773897)

Surveys, Registries, Interviews
A registry for anyone aged 18 and older who lives in the United States

ShareForCures®: Susan G. Komen's People-Powered, Data-Driven Breast Cancer Research Registry

https://www.facingourrisk.org/research-clinical-trials/study/295 /shareforcures-susan-g-komens-people-powered-data-driven-breast-cancer-research-registry

Clinicaltrials.gov identifier:
NCT05654246 (https://clinicaltrials.gov/show/NCT05654246)

Surveys, Registries, Interviews
Registry for anyone diagnosed with breast cancer

Understanding Risk Factors for Stomach Cancer in People with Inherited Mutations

https://www.facingourrisk.org/research-clinical-trials/study/332 /understanding-risk-factors-for-stomach-cancer-in-people-with-inherited-mutations

Surveys, Registries, Interviews
Online survey on stomach cancer risk for people with an inherited mutation in genes that are linked to an increased risk of certain cancers

REKINDLE: Your Ability to Cope With a Life-Changing Medical Diagnosis

https://www.facingourrisk.org/research-clinical-trials/study/423 /rekindle-your-ability-to-cope-with-a-life-changing-medical-diagnosis

Clinicaltrials.gov identifier:
NCT07002034 (https://clinicaltrials.gov/show/NCT07002034)

Quality of Life
Study for those experiencing mental health struggles due to a diagnosis of cancer or other medical illness

Multi-Cancer Detection Blood Tests in Adults Without Cancer: Vanguard Study

https://www.facingourrisk.org/research-clinical-trials/study/394 /multi-cancer-detection-blood-tests-in-adults-without-cancer-vanguard-study

Clinicaltrials.gov identifier:
NCT06995898 (https://clinicaltrials.gov/show/NCT06995898)

Prevention
A study testing two multi-cancer detection blood tests in people who do not have cancer

Family Study for People with Certain Rare BRCA1 or BRCA2 Variants

https://www.facingourrisk.org/research-clinical-trials/study/428 /family-study-for-people-with-certain-rare-brca1-or-brca2-variants

Surveys, Registries, Interviews
Family study for adults with a known rare BRCA1 or BRCA2 variant in themselves or a relative

Please Help us Learn More About Immunotherapy Side Effects That People With Cancer Experience

https://www.facingourrisk.org/research-clinical-trials/study/421 /a-5-minute-patient-and-caregiver-survey-to-share-experiences-with-immunotherapy-and-any-short-term-or-long-term-side-effects

Surveys, Registries, Interviews
This 5-minute survey allows cancer patients on immunotherapy (currently or in the past) and their caregivers to share their experiences, including their side effects and whether they were resolved or not.

The FYI on MRI: A Decision Support Intervention for Screening Breast MRI for Black and Latina Women

https://www.facingourrisk.org/research-clinical-trials/study/406 /the-fyi-on-mri-a-decision-support-intervention-for-screening-breast-mri

Clinicaltrials.gov identifier:
NCT06892275 (https://clinicaltrials.gov/show/NCT06892275)

Surveys, Registries, Interviews
Feedback survey on materials about breast MRI

Comparing Shorter vs. Standard Radiation for High-Risk Prostate Cancer (High Five)

https://www.facingourrisk.org/research-clinical-trials/study/397 /comparing-shorter-vs-standard-radiation-for-high-risk-prostate-cancer

Clinicaltrials.gov identifier:
NCT05946213 (https://clinicaltrials.gov/show/NCT05946213)

Treatment
Phase 3 treatment study for high-risk prostate cancer

Have You Had A Genetic Counseling Visit For Personal Or Family History Of Cancer?

https://www.facingourrisk.org/research-clinical-trials/study/422 /have-you-had-a-genetic-counseling-visit-for-personal-or-family-history-of-cancer

Surveys, Registries, Interviews
Survey for racially diverse people about their genetic counseling experience

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.